- Home
- JAGX vs CLRB Comparison
JAGX vs CLRB Comparison
Compare JAGX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- CLRB
- Stock Information
- Founded
- JAGX 2013
- CLRB 2002
- Country
- JAGX United States
- CLRB United States
- Employees
- JAGX N/A
- CLRB N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- CLRB Health Care
- Exchange
- JAGX Nasdaq
- CLRB Nasdaq
- Market Cap
- JAGX 12.9M
- CLRB 10.7M
- IPO Year
- JAGX N/A
- CLRB N/A
- Fundamental
- Price
- JAGX $0.85
- CLRB $0.24
- Analyst Decision
- JAGX
- CLRB Buy
- Analyst Count
- JAGX 0
- CLRB 2
- Target Price
- JAGX N/A
- CLRB $28.00
- AVG Volume (30 Days)
- JAGX 542.5K
- CLRB 3.3M
- Earning Date
- JAGX 11-13-2024
- CLRB 11-18-2024
- Dividend Yield
- JAGX N/A
- CLRB N/A
- EPS Growth
- JAGX N/A
- CLRB N/A
- EPS
- JAGX N/A
- CLRB N/A
- Revenue
- JAGX $10,480,000.00
- CLRB N/A
- Revenue This Year
- JAGX $18.18
- CLRB N/A
- Revenue Next Year
- JAGX $40.06
- CLRB N/A
- P/E Ratio
- JAGX N/A
- CLRB N/A
- Revenue Growth
- JAGX N/A
- CLRB N/A
- 52 Week Low
- JAGX $0.84
- CLRB $0.22
- 52 Week High
- JAGX $21.60
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- JAGX 39.11
- CLRB 18.75
- Support Level
- JAGX $0.84
- CLRB $0.27
- Resistance Level
- JAGX $1.33
- CLRB $0.33
- Average True Range (ATR)
- JAGX 0.10
- CLRB 0.03
- MACD
- JAGX -0.03
- CLRB 0.05
- Stochastic Oscillator
- JAGX 1.04
- CLRB 10.38
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.